Anzeige
Mehr »
Freitag, 06.03.2026 - Börsentäglich über 12.000 News
USA erklären Kupfer zur Chefsache - dieser Nevada-Explorer bohrt bereits
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
248 Leser
Artikel bewerten:
(1)

Lunit to Present 5 Abstracts at the ECR Meeting 2022

  • Lunit to present five abstracts highlighting the practical effectiveness of Lunit AI suite in precision diagnostic practices
  • Lunit's AI imaging biomarker leads to better prediction of breast cancer risk
  • Lunit INSIGHT CXR demonstrates its ability as part of a prognosis and intervention prediction model

SEOUL, South Korea, July 11, 2022 /PRNewswire/ -- Lunit has announced the presentation of five abstracts featuring its AI solutions for chest and breast radiology at the European Congress of Radiology (ECR) Meeting 2022, held in Vienna, Austria, July 13th through 17th.

Lunit INSIGHT MMG (left) and Lunit INSIGHT CXR (right)

The ECR, along with the Radiological Society of North America (RSNA), is the world's largest radiology congress, attended by renowned radiologists and medical device giants around the globe.

One of Lunit's presentations will focus on the company's AI-powered imaging biomarker for breast cancer risk assessment in mammography. The study demonstrates the AI-powered Imaging Biomarker in Mammography (IBM), developed by Lunit, making it possible to precisely forecast the risk of breast cancer for the next 5 years with a C-index of 0.684.1

Two joint studies by Lunit and the University of Cambridge explore the possibility of Lunit INSIGHT MMG, an FDA-cleared and CE-marked breast cancer detection AI product, being used to improve the UK breast screening workflow. The studies showed that Lunit INSIGHT MMG could play a role in the double reading screening settings and in particular, could help to increase the detection of interval cancers, which are detected between routine screening cycles.

Furthermore, a joint study with the University of Basel focuses on Lunit's CE-marked chest x-ray AI solution, Lunit INSIGHT CXR. According to the study, the software analyzed 150 chest x-ray images with 97.3% accuracy and reduced the average reading time from 23.2 seconds to 14.1 seconds. The findings indicate that radiologists can substantially improve accuracy and productivity with the assistance of Lunit INSIGHT CXR.

Another major study that used medical data from nine COVID-19 treatment centers in Korea revealed the clinical efficacy of utilizing Lunit INSIGHT CXR as part of the prognosis and intervention prediction model for patients with COVID-19. When Lunit INSIGHT CXR was combined with other clinical modes and data, the model showed significantly improved prediction capabilities for patients' prognosis (e.g., ICU admission, in-hospital mortality) and required medical interventions (e.g., O2 supplementation, mechanical ventilation, use of ECMO).

"Through the studies, Lunit has demonstrated the credibility of our AI-powered diagnostics solutions as well as how AI can make a significant difference in various medical practices," said Brandon Suh, CEO of Lunit. "Based on this achievement, we intend to expand the partnership with global healthcare companies and medical institutions, increasing our market share worldwide."

Lunit Booth

  • Visit us at EXPO X1 - AI area - Booth #30 for product demonstrations of Lunit INSIGHT CXR, Lunit INSIGHT MMG, and Lunit INSIGHT DBT.
    *Some of the products will be available for demonstration also at our global partners' booths: FUJIFILM, Philips, INFINITT Healthcare, SECTRA and AGFA.
  • Available from July 13 to 17, 09:00 - 17:00 CEST

CEO Presentation at the AI Theatre

  • Brandon Suh, CEO of Lunit, will be on stage at the AI Theatre to give an industry presentation about the recent and upcoming product developments, and business activities on how our AI is clinically applied across global medical sites.
  • Title: "Conquer Cancer through AI: Precision Diagnostics in Chest and Breast Radiology"
    When: Wednesday, July 13, 13:25 - 13:31 CEST

Book your meeting with Lunit at ECR 2022 here.

1 C-index: The concordance index is one of the most used performance measures of survival models. It is the probability of concordance between the predicted and the observed survival. C-index 1 indicates perfect prediction accuracy and 0.5 is as good as a random predictor.

Photo - https://mma.prnewswire.com/media/1856293/Lunit_INSIGHT_MMG__left__Lunit_INSIGHT_CXR__right.jpg

Logo - https://mma.prnewswire.com/media/1576401/Lunit_CI_Logo.jpg

© 2022 PR Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.